“We like J & J from a fundamental perspective as one of the cleanest stories in large-cap pharma, with no major near-term patent cliffs or binary risks,”

UBS · said 2026-09-02 · reported 2026-09-03

UBS analysts raised their price target on J&J and cited its superior growth profile and earnings quality.